IL323019A - תרכובות של תרופות עם חלק קושר אלבומין - Google Patents

תרכובות של תרופות עם חלק קושר אלבומין

Info

Publication number
IL323019A
IL323019A IL323019A IL32301925A IL323019A IL 323019 A IL323019 A IL 323019A IL 323019 A IL323019 A IL 323019A IL 32301925 A IL32301925 A IL 32301925A IL 323019 A IL323019 A IL 323019A
Authority
IL
Israel
Prior art keywords
certain embodiments
formula
moiety
group
independently
Prior art date
Application number
IL323019A
Other languages
English (en)
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of IL323019A publication Critical patent/IL323019A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL323019A 2023-03-06 2024-03-05 תרכובות של תרופות עם חלק קושר אלבומין IL323019A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23160258 2023-03-06
EP23195412 2023-09-05
EP23203735 2023-10-16
PCT/EP2024/055724 WO2024184351A1 (en) 2023-03-06 2024-03-05 Compounds of drugs with an albumin binding moiety

Publications (1)

Publication Number Publication Date
IL323019A true IL323019A (he) 2025-10-01

Family

ID=90365191

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323019A IL323019A (he) 2023-03-06 2024-03-05 תרכובות של תרופות עם חלק קושר אלבומין

Country Status (7)

Country Link
CN (1) CN120936383A (he)
AR (1) AR132067A1 (he)
AU (1) AU2024232125A1 (he)
IL (1) IL323019A (he)
MX (1) MX2025010596A (he)
TW (1) TW202440150A (he)
WO (1) WO2024184351A1 (he)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1225290A (he) 1968-06-21 1971-03-17
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
JP5588354B2 (ja) 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
TW201004648A (en) 2008-05-23 2010-02-01 Enzon Pharmaceuticals Inc Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2011012722A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
TWI834720B (zh) * 2018-09-12 2024-03-11 瑞典商奎亞培格製藥公司 可釋放glp-1共軛物
AU2019348440B2 (en) 2018-09-26 2024-09-12 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
US20210330798A1 (en) * 2018-09-26 2021-10-28 Ascendis Pharma A/S Treatment of infections
CN114286693A (zh) 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
MX2022014907A (es) 2020-05-26 2023-01-04 Univ Indiana Res & Tech Corp Analogos de la hormona paratiroidea para el tratamiento del hipoparatiroidismo.
US20250268986A1 (en) 2020-11-06 2025-08-28 Novo Nordisk A/S Glp-1 prodrugs and uses thereof
EP4281464A4 (en) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders

Also Published As

Publication number Publication date
WO2024184351A1 (en) 2024-09-12
TW202440150A (zh) 2024-10-16
AU2024232125A1 (en) 2025-08-28
AR132067A1 (es) 2025-05-21
CN120936383A (zh) 2025-11-11
MX2025010596A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
AU2020286303B2 (en) PTH prodrugs
JP2022110084A (ja) 増加したｎｅｐ安定性を有する徐放ｃｎｐ作動薬
JP7085535B2 (ja) ピーク対トラフ比が小さいｐｔｈ化合物
CA3007982C (en) Controlled-release cnp agonists with low initial npr-b activity
JP7039574B2 (ja) 放出制御ｐｔｈ化合物の漸増用量設定
KR20190074292A (ko) 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
CA3007987C (en) Controlled-release cnp agonists with low npr-c binding
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
CA3008017C (en) Controlled-release cnp agonists with reduced side-effects
KR20200139730A (ko) Il-2 접합체
AU2013328774A1 (en) Diagnosis, prevention and treatment of diseases of the joint
RS64440B1 (sr) Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
IL323039A (he) תרכובות של תרופות המכילות חלקים קושרי אלבומין
AU2024233842A1 (en) Multi-albumin binding compounds
IL323019A (he) תרכובות של תרופות עם חלק קושר אלבומין
KR20250169638A (ko) 알부민 결합 모이어티를 갖는 약물의 화합물
RU2798085C2 (ru) Пролекарство, содержащее саморасщепляемый линкер
RU2798085C9 (ru) Пролекарство, содержащее саморасщепляемый линкер
HK40007777A (en) Pharmaceutical composition for controlling the pth release
HK40007965A (en) Pth compounds with low peak-to-trough ratios
HK40000751B (zh) Pth前药
HK40007776B (zh) 控释pth化合物的剂量方案
HK40000751A (en) Pth prodrugs